All In Biotech

Drug Trial Radar · NCT07480941

Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma

A Phase 1, First-in-Human, Biomarker-Guided, Dose-Escalation and Expansion Study of Locoregional Dual-Targeting CAR-NK Cells Directed Against IL13Rα2, EGFR/EGFRvIII, and/or B7-H3 (CD276) in Adults With Recurrent or Progressive Glioblastoma or High-Grade Glioma

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Feb 18, 2027

Study completion Mar 17, 2028

Sponsor

Lead sponsor
Beijing BiotechIndustry
Sponsor type
Industry
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent or progressive glioblastoma (GBM) or other high-grade glioma (HGG). Participants will undergo tumor antigen profiling for IL13Rα2, EGFR/EGFRvIII, and B7-H3 (CD276). Based on this assessment, each participant will receive the most suitable dual-target CAR construct to reduce antigen-escape risk.

Conditions

  • Glioblastoma
  • High-grade Glioma
  • Malignant Glioma
  • Recurrent Glioblastoma
  • Recurrent High-grade Glioma

Interventions

  • Dual-target CAR-NK cellsBiological

    Dual-target CAR-NK cells

  • CyclophosphamideDrug

    Cyclophosphamide

  • FludarabineDrug

    Fludarabine

  • Intracranial catheter/reservoir for locoregional deliveryDevice

    Intracranial catheter/reservoir for locoregional delivery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs)Time frame: 28 Days
  2. Maximum tolerated dose (MTD)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.